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Abstract
Background: A vaginal fistula is a devastating condition, affecting an estimated 2 million girls and women across
Africa and Asia. There are numerous challenges associated with providing fistula repair services in developing
countries, including limited availability of operating rooms, equipment, surgeons with specialized skills, and funding
from local or international donors to support surgeries and subsequent post-operative care. Finding ways of
providing services in a more efficient and cost-effective manner, without compromising surgical outcomes and the
overall health of the patient, is paramount. Shortening the duration of urethral catheterization following fistula
repair surgery would increase treatment capacity, lower costs of services, and potentially lower risk of healthcare-
associated infections among fistula patients. There is a lack of empirical evidence supporting any particular length
of time for urethral catheterization following fistula repair surgery. This study will examine whether short-term (7
day) urethral catheterization is not worse by more than a minimal relevant difference to longer-term (14 day)
urethral catheterization in terms of incidence of fistula repair breakdown among women with simple fistula
presenting at study sites for fistula repair service.
Methods/Design: This study is a facility-based, multicenter, non-inferiority randomized controlled trial (RCT)
comparing the new proposed short-term (7 day) urethral catheterization to longer-term (14 day) urethral
catheterization in terms of predicting fistula repair breakdown. The primary outcome is fistula repair breakdown up
to three months following fistula repair surgery as assessed by a urinary dye test. Secondary outcomes will include
repair breakdown one week following catheter removal, intermittent catheterization due to urinary retention and
the occurrence of septic or febrile episodes, prolonged hospitalization for medical reasons, catheter blockage, and
self-reported residual incontinence. This trial will be conducted among 512 women with simple fistula presenting
at 8 study sites for fistula repair surgery over the course of 24 months at each site.
Discussion: If no major safety issues are identified, the data from this trial may facilitate adoption of short-term
urethral catheterization following repair of simple fistula in sub-Saharan Africa and Asia.
Trial registration: ClinicalTrials.gov Identifier NCT01428830.
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A vaginal fistula is a devastating condition, and while
true prevalence is unknown, it is estimated to affect 2
million girls and women across Africa and Asia. The
primary cause of a vaginal fistula is prolonged
obstructed labor: the fetus’s head compresses the soft
tissues of the bladder, vagina and rectum against the
woman’s pelvis, cutting off blood supply to the tissue,
causing the tissue to die and slough away. The result is
an abnormal opening between the vagina and bladder,
or between the vagina and rectum, or both, and either
urinary and/or fecal incontinence.
Approximately 80-95% of vaginal fistula can be closed
surgically [1]; however, the provision of fistula repair ser-
vices in developing countries is not without challenges.
Specialized training and skills are necessary, especially to
handle more complex cases, and this limits the availabil-
ity of services. Women with fistula are predominantly
poor and from rural areas, and often cannot pay for sur-
gery or transport to a service site. Thus, fistula repair ser-
vices must be provided free of charge. Fistula services are
few and far between in Africa and Asia: the availability of
services depends not only on the availability and motiva-
tion of surgeons with specialized skills, but also the avail-
ability of operating rooms, equipment, and funding from
local or international donors to support both surgeries
and lengthy post-operative care. In most contexts, the
need for repair services exceeds the available human and
infrastructural capacity. Moreover, the prolonged bladder
catheterization that is frequently employed after surgery
translates into a need for longer hospitalization, more
intensive nursing care, and increased costs, leading to
decreased capacity for treating other patients. Longer
duration catheterization may also be associated with
increased risk of healthcare-associated infection. Redu-
cing the duration of bladder catheterization, provided no
compromise in surgical outcomes and patient health, has
important implications for the delivery of fistula care and
treatment services in low resource settings.
Bladder catheterization practices following fistula repair
and other pelvic surgery vary. Publications about fistula
surgery often state that bladder drainage through indwel-
ling urethral catheterization should continue between 10
and 14 days post-operatively [2,3]. However, in both fistula
repair [4] and other types of gynecological surgery [5], the
duration of bladder drainage via indwelling urinary cathe-
ter is primarily based on custom rather than empirical
research, and the duration of drainage varies substantially.
A recent survey of 40 fistula surgeons conducted by
Arrowsmith and colleagues [6] found that catheterization
durations following fistula repair surgery ranged from 5 to
21 days, with 13% of surgeons reporting they catheterize
women for 8 days or less following surgical repair of
simple fistula. Results from a multi-country prospective
cohort study examining predictors of repair outcomes
recently completed by Fistula Care/USAID also found a
wide distribution in post-repair duration of urethral cathe-
terization among 1274 women. The median duration of
catheterization was 21 days, with an interquartile range
(IQR) of 14-27 days [7]. A wide range has also been found
for duration of catheterization following colovesical fistula
repair. A retrospective review of data at Massachusetts
General Hospital conducted by de Moya and colleagues
found that duration of catheterization following colovesi-
cal fistula repair secondary to diverticulitis ranged from 3-
42 days [8]. While colovesical fistula repairs differ consid-
erably from vaginal fistula repairs, these findings nonethe-
less indicate that not only is shorter-term catheterization
currently being implemented for different types of bladder
surgery, but that it may be a feasible alternative to longer
term catheterization following the repair of simple urinary
fistula in women.
Short-term urethral catheterization may in fact pose
no additional risk to patients in terms of repair prog-
nosis. One purpose of post-repair urethral catheteriza-
tion is to provide an opportunity for adequate tensile
strength to develop so that bladder distension does not
disrupt the healing wound. The presumption behind
prolonged catheterization is that the bladder heals better
“at rest” (i.e. when it is not filling and emptying); how-
ever, there is little evidence to support this. For non-
contaminated wound healing in general, the critical per-
iod involving granulation and neovascularization peaks
at 5 days and inflammation is over in 1 week [9], with
matrix deposition and cell proliferation continue until at
least 30 days. Tensile strength increases rapidly during
the first 5 days, although final tensile strength is not
reached until over 100 days. A recent study evaluating
the effects of long-term catheterization on extracellular
matrix (ECM) biological scaffold remodeling following
partial cystectomy in canines, found that early bladder
filling (i.e. shorter duration of catheterization) mediated
a constructive remodeling response [10]. While biologic
scaffolds composed of ECM are a cutting edge innova-
tion not feasible for fistula repair in developing coun-
tries, these results suggest that removing the catheter
early and allowing the bladder to begin filling and emp-
tying, may be beneficial, rather than harmful, to bladder
healing. Nonetheless, no basic physiologic studies on the
dynamics of wound healing in the bladder after fistula
repair have been published to date and it is possible
that the wound healing process following fistula repair
m a yb em o r ep r o l o n g e dt h a nn o t e da b o v eg i v e nt h e
contaminated and chronic nature of most vaginal fistula.
Given the potential benefits of short-term urethral
catheterization, and the fact that it is currently being
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needed to determine the non-inferiority of short-term
urethral catheterization compared to longer-term ure-
thral catheterization. The primary objective of this study
is thus to examine whether short-term (7 day) urethral
catheterization is not worse by more than a minimal
relevant difference to longer-term (14 day) urethral
catheterization in terms of incidence of fistula repair
breakdown among women with simple fistula.
Methods/Design
This will be a non-inferiority randomized controlled
trial (RCT) comparing the new proposed short-term (7
day) urethral catheterization to longer-term (14 day)
urethral catheterization in terms of predicting fistula
repair breakdown, measured 3 months following fistula
repair surgery. This study will be conducted among 512
women with simple fistula presenting at eight study
sites for fistula repair surgery (Table 1). Figure 1 depicts
the flow of study participants.
Intervention
The study intervention will entail removal of the ure-
thral catheter at 7 days after surgery in the intervention
arm and 14 days after surgery in the control arm. While
7 and 14 days are the target days for urethral catheter
removal in the two groups, should it be necessary to
remove the catheter either one day earlier or one day
later (e.g. holiday, surgeon unavailable) in either group
(i.e. 6-8 days or 13-15 days) these women will still be
considered as compliant with the group assignment.
Each patient will receive the same type of catheter, and
with the exception of the timing of catheter removal, all
other procedures related to the removal of the catheter
will remain the same across both study arms. No drugs
or new devices will be examined as part of this study.
Outcome measures
The primary study endpoint is fistula repair breakdown
any time after day 7 after urethral catheter removal up
to three months following surgery. Repair breakdown
will be assessed using a dye test; a urinary catheter will
be inserted into the bladder, saline colored with dye will
be introduced into the bladder via the catheter, and the
suture line will be checked for leaks.
Secondary outcomes will include: repair breakdown
one week following indwelling urethral catheter removal,
the need for intermittent catheterization to manage
urinary retention, and the occurrence of septic or febrile
episodes, prolonged hospitalization, catheter blockage,
and self-reported residual incontinence. Prolonged hos-
pitalization will be defined as a stay at the facility
beyond one week following initial catheter removal for
medical reasons.
Study population
All women who present at study sites for fistula repair
surgery will be potentially eligible. Women will be ran-
domized if:
￿ they have a “simple” fistula, based on the surgeon’s
perception during surgery
￿ they have a closed fistula at completion of surgery
￿ they have a closed fistula 7 days after surgery
￿ they understand study procedures and requirements
￿ they agree to return to the facility for one follow-up
visit three months after the date of surgery
￿ they provide informed consent to participate in the
study
￿ they have no contraindications precluding their
participation
Women will be excluded if they have a fistula that is:
￿ determined to be “not simple”
￿ radiation-induced, associated with cancer or due to
lymphogranuloma venereum
￿ not closed immediately after surgery or 7 days after
surgery
Generation of allocation sequence
Randomization will be done using permuted blocks
within site to ensure similarity of groups with regard to
potential confounding factors that might influence
repair outcomes within a particular study site. The ran-
dom allocation sequence will be generated centrally at
the World Health Organization (WHO) Headquarters
using computer generated random numbers. Randomi-
zation will be to two groups and stratified by site. Block-
ing with randomly varying groups will be used to
restrict randomization within the strata. Each site will
recruit 64 participants.
Random allocation technique and allocation concealment
Allocation of the random generated sequence will be by
consecutively numbered envelopes. Allocation conceal-
ment will be achieved by using sealed opaque envelopes.
Table 1 Study sites
Country Site
Democratic Republic of
Congo
Hôpital Saint Joseph de Kinshasa
Ethiopia Gondar University Hospital Fistula Unit
Guinea Prefectural Hospital of Kissidougou
Kenya Kenyatta National Hospital
Niger Maternité centrale de Zinder
Nigeria National Obstetric Fistula Centre
Abakaliki
Sierra Leone Aberdeen Women’s Centre
Uganda Kagando Hospital
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Rationale for the non-inferiority hypothesis and for
sample size estimation
The research question of interest is whether short-term
catheterization is not worse by more than a minimal
relevant difference than longer-term catheterization in
terms of achieving fistula closure. This question lends
itself to a non-inferiority design.
The choice of a non-inferiority margin, i.e. the smal-
lest clinical difference that is acceptable between the
two treatments, is based on a combination of clinical
judgment and statistical reasoning. Because there are no
data from previous trials to help define the clinical dif-
ference between treatments, we have relied on our own
Women consent to participate in 
study
Fistula repair surgery 
Fistula considered simple  
at end of surgery
Fistula considered not simple at 
end of surgery
Ineligible Dye test at end of surgery
Dye test negative at end of 
surgery
Dye test positive at end of 
surgery
Ineligible Dye test at 7 days
7 day dye test negative 7 day dye test positive 
Randomization Ineligible
Randomized to 7 day removal. 
Catheter removed at 7 days
Randomized to 14 day removal
Catheter removed at 14 days
Urine retention assessment & 
treatment as needed
Dye test at 14 days post-surgery
14 day dye test negative 14 day dye test positive
Assessment 3 months following 
surgery
Repair breakdown. Participation 
in study ends.
Urine retention assessment & 
treatment as needed
Dye test at 21 days post surgery
21 day dye test negative 21 day dye test positive
Assessment 3 months following 
surgery
Repair breakdown. Participation 
in study ends.
Figure 1 Trial profile. Women who consent to participate in the study may be determined ineligible prior to randomization: (1) at the time of
surgery if the surgeon determines that the fistula is ‘not simple’: (2) at the end of surgery if the fistula is not closed based on dye test results;
and (3) 7 days after surgery if the fistula is not closed based on dye test results. Seven days after surgery, women with a closed fistula will be
randomized to catheter removal on that day (i.e. the 7-day removal group) or to have the catheter kept in place for an additional 7 days (i.e. the
14-day removal group). Women will remain at the study site for an additional 7 days after catheter removal. On days 1, 3 and 7 after catheter
removal, urine retention will be assessed and intermittent catheterization employed as needed. Women with a positive urinary dye test at 7 days
following catheter removal will be classified as having experienced a repair breakdown and their participation in the study will be completed.
Remaining women will be asked to return for a follow-up visit 3 months after the date of surgery.
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a margin of inferiority of 10% is an irrelevant small dif-
ference. In other words, if the two-sided 95% confidence
interval (95% CI) for the difference in fistula repair
breakdown rates ("7-day” minus “14-day”) lies fully to
the left of the 10% non-inferiority margin, we will have
proved non-inferiority of the “7-day” procedure at the
level of significance a = 0.025; superiority (as a bonus)
will be demonstrated at the level of significance a =
0.05 if the two-sided 95% CI lies fully to the left of 0.
Analyses were conducted using preliminary data from
the Fistula Care/USAID prospective cohort study exam-
ining fistula repair outcomes in order to determine the
probability of successful closure in women with simple
fistula catheterized for longer periods of time (i.e. the
equivalent of the “standard” treatment group in the
study outlined here). Among the women with simple
repairs in the prospective study for whom follow-up
data were available (n = 145), 87% had a closed fistula
at 3 months follow up. Thus, we believe that it is rea-
sonable to expect the failure rate (e.g. proportion of fis-
tula that are not closed) to be between 10 to 15%.
Assuming 13% failure rate in the control group, non-
inferiority will be demonstrated within the margin of 10%
at a one-sided significance level of 0.025 and a power of
80% (calculated when failure rates in both arms are the
same), with a sample size of 177 per arm (354 women in
total). Adjusting by 20% for loss to follow-up and 10% for
protocol violations and withdrawals, this would result in
a sample size of 507 women. Each site will randomize 64
women, for a total sample size of 512.
Type of data and collection procedure
For all women who have consented to participate, data will
be collected, at hospital level, at three time points using
case report forms (CRFs) developed for the study: i) prior
to surgery, detailed information on socio-demographic
characteristics of the women, duration of the fistula, pre-
vious attempts at repairing the fistula and pre-operative
care procedures will be recorded; ii) at the time of surgery,
a detailed clinical examination will be conducted to assess
the characteristics of the fistula, and to allow the surgeon
to determine if he/she would consider the fistula “simple”
or not. For all participants, detailed information will be
recorded on the anatomical and clinical characteristics of
the fistula(s), including the presence of scarring, location
and type of the fistula and length and width of the fistula;
iii) post-surgery, at 1, 3, 7 and 90 days after surgery. Com-
pleted CRFs will be sent periodically to the data manage-
ment centre at the WHO in Geneva for data entry.
Analysis plan
The primary outcome of the trial is repair breakdown at
3 months or earlier in an intent-to-treat (ITT) analysis.
The primary analysis will be conducted for the ITT
population. The ITT population would include patients
for whom the protocol is violated (i.e. patients who are
randomized to short-term catheterization but are in fact
catheterized for longer durations, or patients who are
randomized to the long-term catheterization group but
are in fact catheterized for only 7 days) and withdrawals.
Unlike a superiority trial, where the treatment effect is
the primary parameter of interest, the interpretation of a
non-inferiority trial’s results depends on the location of
the CI for the effect of the experimental treatment rela-
tive to the margin of non-inferiority (Δ)a n dan u l l
effect. A range of possible scenarios are depicted in Fig-
ure 2, where error bars indicate 2-sided 95% CIs, and
the tinted area indicates the zone of inferiority. Thus,
primary analyses will be interpreted as follows: if the
whole 95% CI lies to the right of the non-inferiority
margin of 10% (scenario H), the experimental interven-
tion will be declared “inferior.” If the whole 95% CI lies
below the non-inferiority margin, the intervention will
be considered to be non-inferior to the standard treat-
ment (scenarios B-D). If the 95% CI includes the non-
inferiority margin Δ (scenarios E, F and G) study results
will be deemed inconclusive. Finally, in scenario A, since
the 95% CI lies completely to the left of zero, the new
treatment may be considered superior to the standard
treatment [11].
Figure 2 Interpreting results of non-inferiority trials [11].
Footnotes for Figure 2. *This CI indicates noninferiority in the sense
that it does not include Δ, but the new treatment is significantly
worse than the standard. Such a result is unlikely because it would
require a very large sample size. †This CI is inconclusive in that it is
still plausible that the true treatment difference is less than Δ, but
the new treatment is significantly worse than the standard.
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to then test the hypothesis that the new treatment is
superior to the active control, with a significance level
defined a priori and with an ITT analysis [12].
Interim data analysis
A Data Safety and Monitoring Board (DSMB) with no
direct involvement in the trial will be appointed. The
role of the DSMB will be to deal with any ethical issues
that may arise while the trial is in progress, and to scru-
tinize an interim analysis. An interim analysis will be
conducted to be reviewed by the DSMB after one-third
of the study participants have returned for the three-
month follow-up visit. At the time of the interim ana-
lyses, event and recruitment rates will be provided to
the DSMB by unmasked treatment group.
Stopping the trial
The DSMB will be asked to give advice regarding stopping
the trial if they have proof beyond doubt of an important
advantage or disadvantage for one of the treatment
groups, and they consider that the results are likely to
affect clinical practice. For the outcomes of the trial, the
following stopping guidelines are proposed for the DSMB:
(1) At the time of the interim analysis, the DSMB may
recommend stopping the study or temporarily halting
recruitment if there are significantly more repair break-
downs in one catheterization group compared to the
other; a difference between the two treatment arms will
be considered significant if the p value for the difference
is less than 0.001.
(2) In the event that the interim analysis shows nota-
bly more adverse events in either study arm, the DSMB
may recommend stopping the study or temporarily halt-
ing recruitment.
(3) The DSMB may also recommend stopping the
study, temporarily halting recruitment or adjusting
study sites if it seems that recruitment is not proceeding
at rates that will allow the study to reach its target sam-
ple size in a reasonable timeframe.
It should be noted that if there appears to be an unex-
pectedly high number of repair breakdowns among
short-term catheterization cases compared to long-term
catheterization cases either as reported by study site
staff or the study monitor, or based on the interim ana-
lysis, any one of the study Institutional Review Boards
(IRBs) may also temporarily or permanently halt the
study at any time.
If the study is stopped temporarily or permanently for
any reason, follow-up of women already enrolled will
continue as originally scheduled and all women already
enrolled will receive continued care, appropriate to their
clinical condition and circumstances, in line with each
sites standard practice.
Duration of project
It is anticipated that the recruitment into the trial and
all follow-up of participants can be completed in
approximately 2 years. Recruitment will begin in
December 2011 after trial procedures have been tested,
study staff trained and materials have been distributed
to the study sites.
Discussion
I fn om a j o rs a f e t yi s s u e sa r ei d e n t i f i e d ,t h ed a t af r o m
this trial may facilitate adoption of short-term catheteri-
zation following repair of simple fistula in various coun-
tries in sub-Saharan Africa and Asia. The adoption of
short-term catheterization will have important implica-
tions for service delivery, and potentially, patient health
outcomes. For instance, Nardos and colleagues calcu-
lated the implications of urethral catheterization dura-
tion at the Addis Ababa Fistula Hospital, where
approximately 1200 fistula repairs are performed
annually. They reported that assuming no compromise
in patient outcomes, a four day reduction in postopera-
tive hospitalization due to early bladder catheter
removal (10 vs. 14 days) would allow the number of
patients who could receive surgical care to be increased
by 20% [9]. In light of the wide range of catheterization
durations practiced in sub-Saharan Africa and Asia
[6,7], the potential benefit associated with short-term
catheterization with regard to increased access to sur-
g e r yf o rw o m e nw i t ho b s t e t r i cf i s t u l am a yb es i g n i f i -
cantly greater. In addition, short-term duration of
urethral catheterization may also decrease risk of urinary
tract infection (UTI). For instance, a recent Cochrane
review of urinary catheterization following urogenital
surgery in adults examined seven trials which compared
shorter postoperative duration of catheter use to longer
duration; these trials suggested that shorter-term cathe-
terization was associated with fewer UTIs [13]. In sum,
short-term urethral catheterization has the potential to
reduce hospital stays for women, thus freeing bed space,
reducing costs per patient, and allowing for a greater
number of patients to receive clinical care. It may also
have implications for the probability of infection, and
possibly sepsis, following surgery. Irrespective of study
outcome, the results of this study will be disseminated
in at least one workshop/forum attended by fistula sur-
geons, regional/local meetings, and at least one publica-
tion in a peer-reviewed journal.
Technical and Ethical Approvals
The protocol received technical and ethical approval
from the WHO Research Project Review Panel (RP2)
and Research Ethics Review Committee, respectively.
Ethical approval will be obtained from appropriate
national and institutional ethical review bodies as
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pants at any given site will not begin until all the neces-
sary local ethical approvals have been obtained.
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